For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Levomepromazine - Nausea and vomiting
PAD Profile : Levomepromazine - Nausea and vomiting
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
Other Indications
- Lambert-Eaton myasthenic syndrome (LEMS)
- Pain
- Osteoarthritis
- Constipation
- Hepatic encephalopathy
- Travellers diarrhoea
- Penile rehabilitation
- Erectile dysfunction
- Hyperuricaemia and Gout
- Dysphagia
- Diarrhoea
- Haemorrhoids
- Low sexual desire in menopausal women
- Bacterial infection
- Inflammatory bowel disease
- Psoriasis
- Atopic dermatitis
- Multiple sclerosis
- Cystic fibrosis
- Duchenne muscular dystrophy
- Cystic fibrosis
- Tuberculosis
- Multiple sclerosis
- Tuberculosis
- Cystic fibrosis
- Systemic Lupus Erythematosus
- Inclusion body myositis
- Systemic Lupus Erythematosus
- Duchenne muscular dystrophy
- Systemic Lupus Erythematosus
- Multiple sclerosis
- Short bowel syndrome
- Any paediatric use
- Erectile dysfunction combination therapy
- Children and young people with Epilepsy
- Mental Health disorders
- Mental Health disorders
- Inflammatory bowel disease
- Acne
- Diabetes Mellitus
- Interface Prescribing Policy (IPP)
- Non-acne dermatological indications
- Restless Leg Syndrome
- Bacterial skin and skin structure infections
- Narcolepsy
- Bacterial lung infection (non-cystic fibrosis)
- Menopausal disorders
- All
- Atopic dermatitis
- Psoriasis
- Clostridioides difficile
- Covid-19
- Covid-19
- Covid-19
- Inflammatory bowel disease
- Inflammatory bowel disease
- Migraine (prevention)
- Dry eyes
- Cancer
- Diarrhoea
- Inflammatory bowel disease
- Non-radiographic axial spondyloarthritis
- Photoaggravated dermatoses
- Photodermatoses
- Metabolic disorders
- Insomnia in adults
- Cardiomyopathy
- Epidermolysis bullosa
- Photoaggravated dermatoses
- Psoriasis
- Psoriatic arthritis
- Photodermatoses
- Photodermatoses
- Photoaggravated dermatoses
- Catheter maintenance solutions
- Dry eyes
- Dry eyes
- Dry eyes
- Dry eyes
- Dry eyes
- Dysphagia
- Prurigo nodularis
- Vitamin D deficiency and insufficiency
- Osteoporosis
- Migraine (prevention)
- Pain
- Ankylosing spondylitis
- Non-radiographic axial spondyloarthritis
- Pustular psoriasis
- Mucus clearance
- Atopic dermatitis
- Alopecia
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Smoking cessation
- Pain
- Homozygous familial hypercholesterolaemia
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Metabolic disorders
- Concious sedation
- Premedication
- post Bariatric surgery
- Erectile dysfunction
- Parkinson's disease
- Myasthenia gravis
- Bacterial infection
- Bacterial infection
- Bacterial infection
- Bacterial infection
- Bacterial infection
- Bacterial infection
- Tuberculosis
- Tuberculosis
- Tuberculosis
- Covid-19
- Inflammatory bowel disease
- Rehydration in short bowel syndrome
- Faecal impaction (adults)
- Faecal impaction (children)
- Minor digestive complaints
- Haemorrhoids
- Haemorrhoids
- Menopausal disorders
- Menopausal disorders
- Menopausal disorders
- Menopausal disorders
- Menopausal disorders
- Menopausal disorders
- Menopausal disorders
- Menopausal disorders
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Agitation in mania and psychotic disorders
- Schizophrenia
- Intraoperative mydriasis / prevention of miosis
- Stoma
- Arrhythmias
Additional Documents
No additional documents returned.
Committee Recommendations
Excluding palliative care.
Tablets 6.25mg and Oral solution 5mg/ml
This drug has not yet been assessed for formulary status [for 2nd/3rd line refractory nausea and vomiting] and is not currently on the APC work-plan.
This drug has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.
Before prescribing this drug/device it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.
The APC will consider recommending the prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net if they wish to make a submission.